Consensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy. A NEURON Living Guideline Project
- PMID: 40590046
- PMCID: PMC12206896
- DOI: 10.2147/JPR.S521788
Consensus Guidelines from the American Society of Pain and Neuroscience for the Use of 60-Day Peripheral Nerve Stimulation Therapy. A NEURON Living Guideline Project
Abstract
Peripheral nerve stimulation (PNS) has evolved with various applications and durations of therapy. In recent years, extensive data has been developed on a 60-day treatment using a novel approach. Confusion exists on the use of a trial therapy, a permanent implant, and a 60-day duration treatment. The American Society of Pain and Neuroscience (ASPN) seeks to clarify the literature associated with this neuromodulation approach. A diverse group of experts was nominated to provide opinions and guidance based on evidence-graded assessment and clinical knowledge. This guidance is the first to specifically assess the clinical use of 60-day PNS and best medical practice.
Keywords: best practices; clinical guidelines; pain medicine; peripheral nerve stimulation.
© 2025 Gill et al.
Conflict of interest statement
Usman Latif: Consultant: Abbott, Brixton Biosciences, Hydrocision, Nalu Medical, Nevro, Omnia Medical, Saluda, Spinal Simplicity, SPR Therapeutics, Stryker, Vertos Medical, Vivex Biologics; Research funding: Mainstay Medical, Spinal Simplicity, Vivex Biologics; Stock: InFormed Consent, Spinal Simplicity. Scott Pritzlaff: Consultant SPR Therapeutics, Bioventus, Nalu Medical; Education grants from Abbott, Biotronik, Medtronic, and Nevro; Royalties from Wolters Kluwer. Ioannis Skaribas: Consultant Abbott, Nalu. Hemant Kalia: Consultant Abbott, Averitas, Nalu, Curonix, SPR Therapeutics, Nervonik, Virdio Health. Samir Sheth: Consultant SPR, Medtronic, Vertos, Boston Scientific, SI Bone; Royalties from Wolters Kluwer. Madi Schnur: Consultant SPR Therapeutics. Sean Li: Consultant Abbott, Avanos, Averitas Pharma, Boston Scientific, Biotronik, Medtronic, Nalu Medical, PainTeq, Presidio, Saluda, SPR Therapeutics, Stryker; Research funding Avanos, Averitas Pharma, Nevro, Presidio, SPR Therapeutics, Stock options NeuroOne, Nalu Medical. Denise Lester: the Primary Investigator for the RESET trial; Research funding from SPR Therapeutics. Ramana Naidu: Consultant Abbott, Avanos, Boston Scientific, Bioventus, Biotronik, Medtronic, Nalu Medical, Nervonik, SPR Therapeutics. Royalties from McGraw-Hill. David Russo: Consultant Nalu, Nevro. Einar Ottestad: Consultant for BioVentus, SPR Therapeutics, Coloplast; Stock options for Restera Medical; Co-founder Altamont Medical. Henry Vucetic: Consultant Abbott, SPR Therapeutics, Vertos, Saluda, Boston Scientific. David Abejón: Proctor Abbott, Medtronic, Boston Scientific, Cardiva, MBA, Saluda Medical. Mehul Desai: Consultant Medtronic, Nalu Medical Stock Options AllaiHealth, HypreVention, SPR Therapeutics, SynerFuse, Virdio Health, Royalties Oxford Medical. David Dickerson: Consultant SPR, Stryker, Nalu, Vertos, Vertex, Abbott, Biotronik; Research support Abbott, SPR. Amitabh Gulati: Consultant for SPR therapeutics, Nalu Medical, Medtronic, AIS healthcare, Neurovasis, Tersera Medical, Hinge Health, Menda Health, Veritas Pharma. Sayed Dawood: Stock Options Spr, Painteq, Mainstay; personal fees from Abbott, Saluda. Timothy Deer: consultant research Abbott, SpineThera, Saluda Medical, Cornerloc, Boston Scientific, personal fees, Pain Teq, Spinal Simplicity, Biotronik, Aurora, Nervonik, SPR Therapeutics, outside the submitted work; In addition, Dr Timothy Deer has a patent pending to Abbott. The other authors report no conflicts of interest in this work.
Figures
References
-
- Gildenberg PL. History of electrical neuromodulation for chronic pain. Pain Med. 2006;7(s1):S7–S13.
LinkOut - more resources
Full Text Sources
